Clinical Trial Update: Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating oregovomab in combination with bevacizumab and chemotherapy for BRCA wild-type platinum-sensitive recurrent ovarian cancer is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Oregovomab (oregovomab)

Snippet

Sponsor: CanariaBio Inc. | Conditions: Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING